Key result
MRA use at discharge for acute decompensated heart failure was associated with a lower 1-year risk of death or heart failure hospitalization versus no MRA (HR 0.81; 95% CI 0.70-0.93; P=.003).
Why the study?
Data are scarce on the association of mineralocorticoid receptor antagonist use with outcomes in patients with acute decompensated heart failure.
Does mineralocorticoid receptor antagonist use at discharge reduce all-cause death or heart failure hospitalization in older adults with acute decompensated heart failure?
Cohort (n=2,068)
Yes
Does mineralocorticoid receptor antagonist use at discharge reduce all-cause death or heart failure hospitalization in older adults with acute decompensated heart failure?
Hazard Ratio: 0.81 (95% CI 0.7–0.93)
Absolute Event Rate: 28.4% vs 33.9%
p-value: p=.003
In older adults hospitalized for acute decompensated heart failure, MRA prescription at discharge was associated with reduced heart failure readmissions but not all-cause mortality.
No takes yet. Share an insight, caveat, or question.
May support MRA at ADHF discharge; hypothesis-generating and requires randomized confirmation before practice change.
Yaku et al. (2019) conducted a cohort in Acute Decompensated Heart Failure (n=2,068). Mineralocorticoid receptor antagonist (MRA) vs. No MRA use was evaluated on Composite of all-cause death or heart failure hospitalization after discharge (HR 0.81, 95% CI 0.70-0.93, p=.003). MRA use at discharge for acute decompensated heart failure was associated with a lower 1-year risk of death or heart failure hospitalization versus no MRA (HR 0.81; 95% CI 0.70-0.93; P=.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: